[go: up one dir, main page]

JP5176035B2 - Ｄｒｅｆを分子標的とする癌治療用組成物 - Google Patents

Ｄｒｅｆを分子標的とする癌治療用組成物 Download PDF

Info

Publication number
JP5176035B2
JP5176035B2 JP2008538780A JP2008538780A JP5176035B2 JP 5176035 B2 JP5176035 B2 JP 5176035B2 JP 2008538780 A JP2008538780 A JP 2008538780A JP 2008538780 A JP2008538780 A JP 2008538780A JP 5176035 B2 JP5176035 B2 JP 5176035B2
Authority
JP
Japan
Prior art keywords
dref
sequence
nucleic acid
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008538780A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2008044787A1 (ja
Inventor
啓隆 長田
隆 高橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya University NUC
Aichi Prefecture
Tokai National Higher Education and Research System NUC
Original Assignee
Nagoya University NUC
Aichi Prefecture
Tokai National Higher Education and Research System NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya University NUC, Aichi Prefecture, Tokai National Higher Education and Research System NUC filed Critical Nagoya University NUC
Priority to JP2008538780A priority Critical patent/JP5176035B2/ja
Publication of JPWO2008044787A1 publication Critical patent/JPWO2008044787A1/ja
Application granted granted Critical
Publication of JP5176035B2 publication Critical patent/JP5176035B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008538780A 2006-10-06 2007-10-05 Ｄｒｅｆを分子標的とする癌治療用組成物 Expired - Fee Related JP5176035B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008538780A JP5176035B2 (ja) 2006-10-06 2007-10-05 Ｄｒｅｆを分子標的とする癌治療用組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006275695 2006-10-06
JP2006275695 2006-10-06
PCT/JP2007/070031 WO2008044787A1 (fr) 2006-10-06 2007-10-05 Composition pour le traitement du cancer à l'aide de dref comme cible moléculaire
JP2008538780A JP5176035B2 (ja) 2006-10-06 2007-10-05 Ｄｒｅｆを分子標的とする癌治療用組成物

Publications (2)

Publication Number Publication Date
JPWO2008044787A1 JPWO2008044787A1 (ja) 2010-02-18
JP5176035B2 true JP5176035B2 (ja) 2013-04-03

Family

ID=39282971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008538780A Expired - Fee Related JP5176035B2 (ja) 2006-10-06 2007-10-05 Ｄｒｅｆを分子標的とする癌治療用組成物

Country Status (2)

Country Link
JP (1) JP5176035B2 (fr)
WO (1) WO2008044787A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109477146B (zh) 2016-05-10 2023-09-19 国立大学法人东京医科齿科大学 炎症促进因子表达抑制剂、其有效成分的筛选方法、对该方法有用的表达盒、诊断药和诊断方法
SG11202004097RA (en) * 2017-11-09 2020-06-29 Univ Nat Corp Tokyo Medical & Dental Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
CN109777800A (zh) * 2017-11-15 2019-05-21 信雅生物科技（苏州）有限公司 一种能够特异性抑制ZBED1基因的siRNA的构建方法及其应用
CN118910050B (zh) * 2024-07-19 2025-06-10 威海市立医院 一种靶向沉默ALIX基因表达的shRNA、慢病毒表达载体和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012055641; Ｊ．ＢＩＯＬ．ＣＨＥＭ． ＶＯＬ．２７８，　ＮＯ．２５, 2003, Ｐ．２２９２８-２２９３８ *
JPN6012055642; ＭＯＬ．ＣＥＬＬ．ＢＩＯＬ． ＶＯＬ．２７，　ＮＯ．６, 2007, Ｐ．２００３-２０１３ *

Also Published As

Publication number Publication date
JPWO2008044787A1 (ja) 2010-02-18
WO2008044787A1 (fr) 2008-04-17

Similar Documents

Publication Publication Date Title
Wang et al. PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting alternative splicing of STAT3 exon 23
KR20090040391A (ko) Ｒｅｇ４ 또는 ｋｉａａ０１０１을 과발현하는 암의 예방 및 치료 기술
US10105384B2 (en) Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
JP5176035B2 (ja) Ｄｒｅｆを分子標的とする癌治療用組成物
Weiss et al. Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth
JP5794514B2 (ja) 腫瘍血管新生阻害剤
US9493772B2 (en) Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas
JP2011032236A (ja) 腫瘍血管新生阻害剤
US20240043557A1 (en) A platform to obtain monoclonal antibodies directed against processed tumor-specific antigens
JP6057408B2 (ja) 癌の予防剤および／または治療剤
US8486905B2 (en) Use of FLJ25416 gene
JP4797159B2 (ja) 癌転移抑制用組成物
KR102563931B1 (ko) 스플라이스좀 관련 단백질인 IK의 용도로서 ATM 키나아제 pre-mRNA의 스플라이싱을 조절하는 방법
JP5669271B2 (ja) 腫瘍血管新生阻害剤
WO2008069621A1 (fr) Nouvelle utilisation de gènes mig12 et pio5
JPWO2011115271A1 (ja) 腫瘍血管新生阻害剤
JP5480900B2 (ja) 抗癌剤、癌細胞のアポトーシス誘導方法、及び抗癌剤のスクリーニング方法
Groner Astrid Weiss, Boris Brill, Corina Borghouts, Natalia Delis, Laura Mack &
JP2011105669A (ja) 抗腫瘍剤および抗腫瘍剤のスクリーニング方法
JPWO2011115268A1 (ja) 腫瘍血管新生阻害剤
WO2011019065A1 (fr) Inhibiteur de l'angiogenèse tumorale
JP2005013199A (ja) ｓｉＲＮＡを用いたヒトｂｃｌ−２蛋白質の発現の強い抑制。
JP2018172285A (ja) 細胞内の異常物質蓄積を伴う疾患の治療薬、バイオマーカー、診断薬、並びに、スクリーニング方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121128

LAPS Cancellation because of no payment of annual fees